Autore: Mallé Jurima-Romet

MICHAEL R. BLEAVINS, PhD, is cofounder of MichiganTechnology and Research Institute. He retired fromPfizer/Warner-Lambert/Parke-Davis in 2006 and has twenty-threeyears of experience in pharmaceutical research, development, andbiomarkers with more than sixty-five peer-reviewed publications. CLAUDIO CARINI, MD, PhD, FRCPath, is Chief MedicalOfficer and Vice President for Clinical Research at Fresenius.Previously, Claudio served as Global Head of Translational Medicineat MDS and Global Head of Biomarkers at Hoffmann-La Roche. Claudiohas more than twenty years of experience in the field of immunologyand biomarkers and has authored more than 200 publications ininternational and domestic peer-reviewed journals. MALLÉ JURIMA-ROMET, PhD, is Senior Director forDevelopment and Regulatory Services at MDS Pharma Services, whereshe provides strategic and scientific consulting to pharmaceuticaland biotech sponsors, and leads drug development program teams.Mallé has authored over forty peer-reviewed publications andis an adjunct professor at the University of Montreal. RAMIN RAHBARI, MS, is cofounder and Senior Consultant atInnovative Scientific Management. Previously, Ramin has heldpositions at Pfizer, Synaptic, and Parke-Davis pharmaceuticalcompanies, leading cross-functional biomarker teams.